Vitamin D3 for Life

Live Enlightened

Article

Why Similar Vitamin D Levels Can Produce Different Biological Responses: Full Study

Previous related pageVitamin D, Inflammation and Anaemia-Related Iron Restriction: Study SummaryNext related pageWhy Similar Vitamin D Levels Can Produce Different Biological Responses: Study Summary
Study at a glance

Why can people with similar vitamin D blood levels respond differently?

This evidence review explains why two people with similar vitamin D blood results may respond differently. The usual test measures 25-hydroxyvitamin D, shortened to 25(OH)D. Similar results show similar measured blood levels at that moment. They do not prove identical vitamin D activity in every tissue.

What can affect the body’s response to vitamin D?

Vitamin D must be carried to tissues, changed into an active form and received by cells. Cells also control how quickly it is broken down and which genes respond. These processes differ across tissues and circumstances. Proteins carrying vitamin D, body composition and genetic differences can also affect how a dose changes blood levels. Common genetic effects described here were modest, not complete explanations of a person’s response.

What did studies in people show about vitamin D responses?

In a study of 35 healthy young adults, researchers compared vitamin D3 with a placebo, a treatment without vitamin D. Blood measurements and responses inside cells varied between people. Researchers described high, middle and low responses using several measurements. Related studies found differences in gene activity and in how accessible DNA was to the machinery controlling genes. These categories were not established as permanent personal traits.

Does a strong response in one cell type mean better health?

A strong response in one cell type or measurement does not prove a strong response throughout the body or improved health. Laboratory methods, season and measurement timing also affect comparisons. The usual blood test remains useful, but one result cannot describe all vitamin D-related processes or predict every health outcome.

Read the full article below ↓

Two people can have similar measured serum 25-hydroxyvitamin D [25(OH)D] concentrations without having identical vitamin D biology. The reason is not that the laboratory measurement is meaningless; it is that the measured concentration sits upstream of multiple physiological steps that determine delivery, activation, degradation, receptor signalling, gene regulation and endpoint-specific response. Differences at any of those steps can modify what a similar circulating concentration produces in a particular tissue or person. This is a central part of Functional Vitamin D Status, and it complements the distinction developed in Vitamin D Status vs Vitamin D Effect. For the concise version of this evidence review, see Why Similar Vitamin D Levels Can Produce Different Biological Responses: Study Summary.

Similar 25(OH)D does not mean identical metabolite delivery

Most circulating 25(OH)D is carried by vitamin D-binding protein (DBP), with a smaller fraction bound to albumin and only a very small fraction circulating freely. Total 25(OH)D therefore reflects the combined pool rather than one biologically uniform compartment. Differences in DBP concentration, binding characteristics and tissue uptake can alter the relationship between a total measured concentration and metabolite delivery. That is why Vitamin D Binding Protein Explained and Free vs Total Vitamin D Explained are relevant to inter-individual response.

This should not be simplified into a universal claim that free 25(OH)D is always superior to total 25(OH)D. Some tissues can internalize DBP-bound vitamin D metabolites through receptor-mediated uptake, and the clinical value of free-versus-total measurements varies by context. The important point is narrower: equal total concentrations do not guarantee that every tissue experiences an identical substrate environment.

Activation and degradation change the amount of active hormone available locally

25(OH)D is not the end of the pathway. It can be converted by CYP27B1 to 1,25-dihydroxyvitamin D [1,25(OH)₂D], the high-affinity VDR ligand, while CYP24A1 participates in metabolic inactivation and degradation. The relative activity of these pathways is regulated differently across tissues and physiological contexts. The same substrate concentration in blood can therefore feed different local activation and clearance environments. Vitamin D Enzyme Pathways (CYP27B1/CYP24A1) and Tissue-Specific Vitamin D Metabolism develop this distinction in more detail.

Renal endocrine production of 1,25(OH)₂D is tightly linked to calcium-phosphate physiology, PTH and FGF23. By contrast, extra-renal cells can generate active hormone locally for intracrine or paracrine signalling. A serum 25(OH)D result therefore does not directly reveal the concentration of active hormone produced within every tissue. Local enzyme expression, inflammatory signals, differentiation state and cellular demand can change the downstream response while the circulating precursor appears similar.

VDR abundance and cellular context influence signal interpretation

Even if comparable amounts of active hormone reach two cells, their responses need not be identical. VDR abundance, receptor turnover, chromatin accessibility, transcriptional cofactors and the pre-existing state of the cell all influence how strongly the vitamin D signal is translated into gene regulation. This makes Vitamin D Receptor Sensitivity and Density a direct physiological modifier of functional response rather than a semantic add-on.

In-vitro and in-vivo genomic studies show that vitamin D signalling can affect thousands of regulatory regions and many target genes, but the pattern is time-dependent and cell-type dependent. The same hormone does not activate an identical transcriptomic programme in every tissue. Functional response is therefore partly a property of the receiving biological system, not only of the circulating concentration that supplies the precursor.

Human intervention studies show personalized molecular responsiveness

The VitDbol study provides direct evidence that people can differ in biological response after the same broad intervention. Thirty-five healthy young adults received a large oral vitamin D₃ bolus or placebo, with measurements before supplementation and at several subsequent time points. Although circulating vitamin D metabolites increased after supplementation, the magnitude and pattern of response varied substantially between individuals.

The investigators combined changes in PTH and vitamin D-sensitive molecular parameters to classify participants into high, mid and low responders. This does not prove that the categories are permanent traits or validated clinical phenotypes. It does demonstrate that inter-individual response cannot be reduced to one serum 25(OH)D value. The broader page Vitamin D Response addresses the same principle from the perspective of supplementation and change over time.

Epigenomic work from the same research programme adds another layer. After vitamin D₃ exposure, changes in chromatin accessibility were detectable in peripheral blood mononuclear cells. More recent in-vivo work has likewise reported marked inter-individual variation in epigenomic and transcriptomic responses. These observations do not establish that one person’s immune cells define the response of every organ, but they provide strong mechanistic evidence that downstream vitamin D signalling varies between individuals.

Genetic variation can modify both measured response and pathway behaviour

Genetic variation is one contributor to response heterogeneity. In a randomized controlled trial of vitamin D₃ supplementation, common variants near CYP2R1, CYP24A1 and VDR modified the increase in serum 25(OH)D attributable to supplementation. Variants in GC and CYP2R1 were also associated with baseline concentrations. The effect sizes were modest, but the result is mechanistically coherent: genes governing hydroxylation, degradation, transport and receptor signalling can alter how the pathway handles a given exposure.

This connects directly with Vitamin D Genetics. But genetics should be treated as a modifier, not destiny. A common polymorphism rarely determines an individual’s entire vitamin D response, and association with serum response does not automatically imply a clinically important difference in downstream outcomes. Environmental exposure, body composition, adherence, baseline status, age, health state and tissue context can all interact with the genetic background.

Body composition and distribution affect dose-to-level relationships

Vitamin D is fat soluble and distributes into body compartments rather than remaining confined to blood. Higher body mass and adiposity are repeatedly associated with different dose-to-25(OH)D relationships, meaning the same administered dose can produce different circulating changes. This is not exactly the same question as two people who already have the same measured concentration, but it demonstrates that the path from exposure to blood level is itself individualized. Once a similar level is reached, distribution, storage and tissue release can still influence the temporal pattern of substrate availability.

The key interpretive point is that a single measurement is a snapshot. It does not encode how quickly the concentration was reached, how stable it has been, what dose produced it, or how metabolites are partitioned across tissues. Short-Term vs Long-Term Vitamin D Status is therefore relevant when comparing two apparently similar laboratory values.

Endpoint choice can create apparent response differences

“Biological response” is not one universal endpoint. PTH suppression, intestinal calcium absorption, bone turnover, antimicrobial peptide expression, inflammatory signalling and transcriptomic change are different biological outputs. A person may respond strongly in one pathway and weakly in another. This is one reason a functional vitamin D framework must state which endpoint is being discussed rather than describing someone simply as a “low responder.”

The endpoint problem also guards against overinterpreting molecular personalization. A large change in a vitamin D-responsive gene can establish active signalling in that cell population, but it does not automatically predict fracture risk, infection risk, cardiovascular events or another clinical outcome. Mechanistic response and clinical benefit are linked questions, not identical ones.

Measurement similarity does not remove analytical and temporal uncertainty

Two reported 25(OH)D values may also appear more biologically equivalent than they really are because laboratory measurement itself has uncertainty. Assay method, standardization, biological variability, season, recent supplementation and timing can influence interpretation. The page Limitations of Vitamin D Blood Tests explains why the numerical result should be interpreted as a biomarker estimate rather than an exact coordinate of whole-body vitamin D action.

What similar vitamin D levels can and cannot tell us

A similar serum 25(OH)D concentration tells us that two people have a broadly similar measured circulating status at that sampling point. It does not prove identical free and bound fractions, tissue delivery, local activation, catabolism, VDR competence, chromatin context, gene response or physiological outcome. Those are additional layers of the pathway.

The correct conclusion is not that serum 25(OH)D should be abandoned. It is that the biomarker has a defined function and a defined ceiling. It remains useful for assessing vitamin D status, while functional response requires additional physiological context. This layered interpretation preserves the value of measurement without mistaking one accessible marker for the complete biological system.

Primary scientific sources and publication details

Seuter S, Virtanen JK, Nurmi T, Pihlajamäki J, Mursu J, Voutilainen S, Tuomainen T-P, Neme A, Carlberg C. Molecular evaluation of vitamin D responsiveness of healthy young adults. Journal of Steroid Biochemistry and Molecular Biology. 2017;174:314-321. PMID: 27282116. DOI: 10.1016/j.jsbmb.2016.06.003.

Carlberg C, Seuter S, Nurmi T, Tuomainen T-P, Virtanen JK, Neme A. In vivo response of the human epigenome to vitamin D: A Proof-of-principle study. Journal of Steroid Biochemistry and Molecular Biology. 2018;180:142-148. PMID: 29317287. DOI: 10.1016/j.jsbmb.2018.01.002.

Barry EL, Rees JR, Peacock JL, et al. Genetic Variants in CYP2R1, CYP24A1, and VDR Modify the Efficacy of Vitamin D3 Supplementation for Increasing Serum 25-Hydroxyvitamin D Levels in a Randomized Controlled Trial. Journal of Clinical Endocrinology & Metabolism. 2014;99(10):E2133-E2137. PMCID: PMC4184076. DOI: 10.1210/jc.2014-1389.

Carlberg C. Vitamin D Genomics: From In Vitro to In Vivo. Frontiers in Endocrinology. 2018. PMID: 29875733.

Related reading

Original sources

Source

Molecular evaluation of vitamin D responsiveness of healthy young adults

Published in Journal of Steroid Biochemistry and Molecular Biology (2017).

Publication details

Seuter S, Virtanen JK, Nurmi T, Pihlajamäki J, Mursu J, Voutilainen S, Tuomainen T-P, Neme A, Carlberg C. Molecular evaluation of vitamin D responsiveness of healthy young adults. Journal of Steroid Biochemistry and Molecular Biology. 2017;174:314-321. PMID: 27282116. DOI: 10.1016/j.jsbmb.2016.06.003.

Read more →
Source

Genetic Variants in CYP2R1, CYP24A1, and VDR Modify the Efficacy of Vitamin D3 Supplementation for Increasing Serum 25-Hydroxyvitamin D Levels in a Randomized Controlled Trial

Published in Journal of Clinical Endocrinology & Metabolism (2014).

Publication details

Barry EL, Rees JR, Peacock JL, et al. Genetic Variants in CYP2R1, CYP24A1, and VDR Modify the Efficacy of Vitamin D3 Supplementation for Increasing Serum 25-Hydroxyvitamin D Levels in a Randomized Controlled Trial. Journal of Clinical Endocrinology & Metabolism. 2014;99(10):E2133-E2137. PMCID: PMC4184076. DOI: 10.1210/jc.2014-1389.

Read more →
Source

Vitamin D Genomics: From In Vitro to In Vivo

The vitamin D3 metabolite 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the exclusive high-affinity ligand of the vitamin D receptor (VDR), a transcription factor with direct effects on gene expression.

Publication details

Carlberg C. Vitamin D Genomics: From In Vitro to In Vivo. Frontiers in Endocrinology. 2018. PMID: 29875733.

Read more →